Taro Pharmaceutical Industries Stock Cash Per Share
| TARODelisted Stock | USD 42.97 0.00 0.00% |
Taro Pharmaceutical Industries fundamentals help investors to digest information that contributes to Taro Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Taro Stock. The fundamental analysis module provides a way to measure Taro Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Taro Pharmaceutical stock.
Taro |
Taro Pharmaceutical Industries Company Cash Per Share Analysis
Taro Pharmaceutical's Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current Taro Pharmaceutical Cash Per Share | 21.45 X |
Most of Taro Pharmaceutical's fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Taro Pharmaceutical Industries is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
CompetitionIn accordance with the recently published financial statements, Taro Pharmaceutical Industries has a Cash Per Share of 21.45 times. This is 393.1% higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The cash per share for all United States stocks is notably lower than that of the firm.
Taro Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Taro Pharmaceutical's direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Taro Pharmaceutical could also be used in its relative valuation, which is a method of valuing Taro Pharmaceutical by comparing valuation metrics of similar companies.Taro Pharmaceutical is currently under evaluation in cash per share category among its peers.
Taro Fundamentals
| Return On Equity | 0.0306 | |||
| Return On Asset | 0.0021 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.06 % | |||
| Current Valuation | 735.67 M | |||
| Shares Outstanding | 37.58 M | |||
| Shares Owned By Insiders | 78.48 % | |||
| Shares Owned By Institutions | 13.06 % | |||
| Number Of Shares Shorted | 73.56 K | |||
| Price To Earning | 14.57 X | |||
| Price To Book | 0.89 X | |||
| Price To Sales | 2.59 X | |||
| Revenue | 629.18 M | |||
| Gross Profit | 293.13 M | |||
| EBITDA | 52.6 M | |||
| Net Income | 53.87 M | |||
| Cash And Equivalents | 806.25 M | |||
| Cash Per Share | 21.45 X | |||
| Total Debt | 369.06 M | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 3.60 X | |||
| Book Value Per Share | 47.70 X | |||
| Cash Flow From Operations | 132.39 M | |||
| Short Ratio | 3.20 X | |||
| Earnings Per Share | 1.43 X | |||
| Target Price | 43.0 | |||
| Number Of Employees | 24 | |||
| Beta | 0.56 | |||
| Market Capitalization | 1.62 B | |||
| Total Asset | 2.16 B | |||
| Retained Earnings | 2.41 B | |||
| Working Capital | 950.88 M | |||
| Current Asset | 1.88 B | |||
| Current Liabilities | 245.46 M | |||
| Net Asset | 2.16 B |
About Taro Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Taro Pharmaceutical Industries's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Taro Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Taro Pharmaceutical Industries based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Taro Pharmaceutical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Taro Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Taro Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.Moving against Taro Stock
| 0.9 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.87 | TLK | Telkom Indonesia Tbk | PairCorr |
| 0.85 | HYMTF | Hyundai Motor | PairCorr |
| 0.85 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.78 | PFE | Pfizer Inc Aggressive Push | PairCorr |
The ability to find closely correlated positions to Taro Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Taro Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Taro Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Taro Pharmaceutical Industries to buy it.
The correlation of Taro Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Taro Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Taro Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Taro Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Other Consideration for investing in Taro Stock
If you are still planning to invest in Taro Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Taro Pharmaceutical's history and understand the potential risks before investing.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |